Cartesian Therapeutics (RNAC) Net Equity Issued and Repurchased (2016 - 2026)

Cartesian Therapeutics (RNAC) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $15.4 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $15.4 million in Q1 2026; TTM through Mar 2026 was $15.4 million, a N/A change from a year earlier, with the FY2022 full-year figure at $2.1 million, down 95.92% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $15.4 million, down from $9.4 billion in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for RNAC reached as high as $9.4 billion in Q2 2022 and fell as low as $1.7 million in Q1 2022.